Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 14/20 | 0.55 |
| ▸ | CCR5 | P51681 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | STAT1 | P42224 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15529882 | 0.93 | NAMPT (0.57) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL15528872 | 0.91 | NAMPT (0.55) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL16228876 | 0.90 | NAMPT (0.55) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL15529591 | 0.90 | NAMPT (0.55) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL15529646 | 0.88 | NAMPT (0.54) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL15529411 | 0.88 | NAMPT (0.58) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL15529331 | 0.86 | NAMPT (0.52) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL15529793 | 0.86 | NAMPT (0.57) | NAMPTCYP3A4NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28845684 | 0.86 | NAMPT (0.55) | NAMPTCCR5CYP3A4NPC1RAB9A | |
| SCHEMBL15529340 | 0.85 | NAMPT (0.59) | NAMPTCCR5CYP3A4NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | claimed |
| US-20140336168-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2014-11-13 | — | — | US | claimed |
| US-9758511-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160168134-A1 | NAMPT INHIBITORS | ABBVIE INC. (US) | 2016-06-16 | — | — | US | disclosed |
| US-9296723-B2 | NAMPT inhibitors | ABBVIE INC. (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140336168-A1 | NAMPT INHIBITORS | ABBVIE INC. | 2014-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168134-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885CCR5 4275/4885CYP3A4 4662/4885 |
| US-20140336168-A1 | NAMPT INHIBITORS | NAMPT, NNMT, NAPRT | NAMPT 1/4885CCR5 4275/4885CYP3A4 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.